Compare Stocks: CASI, ASBP, TRAW, and CNSP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$7.90 +3.4%	$6.60	$3.31 ▼ $780.00	$9.90M	0.11	37,835 shs	44,250 shs
CASI CASI Pharmaceuticals	$0.21	$0.21	$0.21 ▼ $3.09	$2.55M	0.91	482,532 shs	N/A
CNSP CNS Pharmaceuticals	$5.83 -0.5%	$5.02	$1.90 ▼ $10.59	$8.57M	3.05	6,760 shs	21,426 shs
TRAW Traws Pharma	$0.54	$0.68	$0.43 ▼ $3.27	$8.30M	1.57	107,304 shs	71,877 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	+3.40%	+10.80%	+20.06%	+41.32%	-98.59%
CASI CASI Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-90.44%
CNSP CNS Pharmaceuticals	-0.51%	+16.37%	+6.00%	+15.45%	+7.76%
TRAW Traws Pharma	0.00%	+1.29%	-11.58%	-63.76%	-59.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$7.90 +3.4%	$6.60	$3.31 ▼ $780.00	$9.90M	0.11	37,835 shs	44,250 shs
CASI CASI Pharmaceuticals	$0.21	$0.21	$0.21 ▼ $3.09	$2.55M	0.91	482,532 shs	N/A
CNSP CNS Pharmaceuticals	$5.83 -0.5%	$5.02	$1.90 ▼ $10.59	$8.57M	3.05	6,760 shs	21,426 shs
TRAW Traws Pharma	$0.54	$0.68	$0.43 ▼ $3.27	$8.30M	1.57	107,304 shs	71,877 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	+3.40%	+10.80%	+20.06%	+41.32%	-98.59%
CASI CASI Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-90.44%
CNSP CNS Pharmaceuticals	-0.51%	+16.37%	+6.00%	+15.45%	+7.76%
TRAW Traws Pharma	0.00%	+1.29%	-11.58%	-63.76%	-59.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	1.00	Sell	N/A	N/A
CASI CASI Pharmaceuticals	2.00	Hold	$4.00	1,827.71% Upside
CNSP CNS Pharmaceuticals	2.00	Hold	$20.00	243.05% Upside
TRAW Traws Pharma	1.80	Reduce	$1.00	85.19% Upside

Current Analyst Ratings Breakdown

Latest CASI, ASBP, TRAW, and CNSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$1.00
8/14/2026	ASBP Aspire Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	ASBP Aspire Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	CNSP CNS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Negative	$1.00
6/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$1.00
6/15/2026	TRAW Traws Pharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral
6/15/2026	TRAW Traws Pharma	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/29/2026	TRAW Traws Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
5/20/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	$10K	1,027.00	N/A	N/A	$9.08 per share	0.87
CASI CASI Pharmaceuticals	$26.85M	0.10	N/A	N/A	$0.12 per share	1.73
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	$12.45 per share	N/A
TRAW Traws Pharma	$2.79M	2.97	$0.76 per share	0.71	$0.11 per share	4.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$24.48M	-$69.62	N/A	N/A	N/A	-11,362.21%	N/A	-177.59%	N/A
CASI CASI Pharmaceuticals	-$39.26M	-$3.01	N/A	N/A	N/A	-183.93%	N/A	-131.54%	N/A
CNSP CNS Pharmaceuticals	-$15.85M	-$23.59	N/A	N/A	N/A	N/A	-204.25%	-141.87%	N/A
TRAW Traws Pharma	$9.17M	-$1.74	N/A	N/A	N/A	N/A	-23,868.92%	-165.52%	N/A

Latest CASI, ASBP, TRAW, and CNSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	TRAW Traws Pharma	-$0.3350	-$0.16	+$0.1750	-$0.16	N/A	N/A
8/12/2026	Q2 2026	CNSP CNS Pharmaceuticals	-$0.24	-$0.38	-$0.14	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	7.99	7.82
CASI CASI Pharmaceuticals	N/A	0.30	0.24
CNSP CNS Pharmaceuticals	N/A	5.86	5.86
TRAW Traws Pharma	N/A	0.93	0.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
CASI CASI Pharmaceuticals	22.23%
CNSP CNS Pharmaceuticals	14.02%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	5.80%
CASI CASI Pharmaceuticals	21.24%
CNSP CNS Pharmaceuticals	0.01%
TRAW Traws Pharma	7.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	1.30 million	1.22 million	N/A
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
CNSP CNS Pharmaceuticals	5	1.46 million	1.46 million	Not Optionable
TRAW Traws Pharma	17	15.37 million	14.00 million	No Data

CASI, ASBP, TRAW, and CNSP Headlines

Recent News About These Companies

HC Wainwright Reaffirms Neutral Rating for Traws Pharma (NASDAQ:TRAW)

1 hour ago | americanbankingnews.com

Traws Pharma shares rise after Q2 loss comes in better than expected

August 17 at 10:14 AM | finance.yahoo.com

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

August 14, 2026 | globenewswire.com

Traws Pharma Announces New At-The-Market Offering Program

July 10, 2026 | tipranks.com

Traws Pharma Stock Dividends | NASDAQ:TRAW | Benzinga

July 8, 2026 | benzinga.com

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

June 22, 2026 | globenewswire.com

Outlook for Bucks County biotech take another hit with second setback for flu drug

June 15, 2026 | bizjournals.com

Traws defers midphase flu study after negative regulatory review

June 15, 2026 | fiercebiotech.comF

Micron, Nebius surge premarket; Traws Pharma tumbles

June 15, 2026 | finance.yahoo.com

Traws Pharma shares slide after UK regulator postpones influenza study

June 15, 2026 | msn.com

Why did TRAW stock slump 28% after hours?

June 13, 2026 | msn.com

Traws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory Review

June 12, 2026 | quiverquant.comQ

Traws Pharma Provides Regulatory Update on Influenza Program

June 12, 2026 | globenewswire.com

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

May 27, 2026 | globenewswire.com

Traws Pharma Updates ATM Equity Offering Prospectus Supplements

May 26, 2026 | tipranks.com

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

May 15, 2026 | globenewswire.com

Traws Pops on Hantavirus Research

May 9, 2026 | baystreet.ca

A hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gains

May 9, 2026 | msn.com

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

May 8, 2026 | benzinga.com

Traws Pharma Advances Development of Clinical Candidates for Hantavirus Treatment

May 8, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI, ASBP, TRAW, and CNSP Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$7.90 +0.26 (+3.40%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$7.68 -0.22 (-2.72%)

As of 08/19/2026 07:44 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

CASI Pharmaceuticals NASDAQ:CASI

$0.21 0.00 (0.00%)

As of 08/18/2026

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CNS Pharmaceuticals NASDAQ:CNSP

$5.83 -0.03 (-0.51%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$5.92 +0.09 (+1.63%)

As of 08/19/2026 07:30 PM Eastern

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Traws Pharma NASDAQ:TRAW

$0.54 0.00 (0.00%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$0.50 -0.04 (-6.48%)

As of 08/19/2026 07:59 PM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CASI, ASBP, TRAW, and CNSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CASI, ASBP, TRAW, and CNSP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CASI, ASBP, TRAW, and CNSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI, ASBP, TRAW, and CNSP Company Descriptions

Aspire Biopharma NASDAQ:ASBP

CASI Pharmaceuticals NASDAQ:CASI

CNS Pharmaceuticals NASDAQ:CNSP

Traws Pharma NASDAQ:TRAW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CASI, ASBP, TRAW, and CNSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CASI, ASBP, TRAW, and CNSP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CASI, ASBP, TRAW, and CNSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI, ASBP, TRAW, and CNSP Company Descriptions

Aspire Biopharma NASDAQ:ASBP

CASI Pharmaceuticals NASDAQ:CASI

CNS Pharmaceuticals NASDAQ:CNSP

Traws Pharma NASDAQ:TRAW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools